Related Experiment Video
Updated: Apr 5, 2026
Quantitation of Protein Expression and Co-localization Using Multiplexed Immuno-histochemical Staining and Multispectral Imaging
Published on: April 8, 2016
Single tumor imaging with multiple antibodies targeting different antigens
Yujing Sun1, Girja Shukla1, Stephanie C Pero1
1Department of Surgery, Vermont Cancer Center, University of Vermont College of Medicine, Burlington, VT, USA.
Abstract:
Antibodies are important drugs for treating cancer and there is strong rationale for using multiple antibodies to improve outcomes. We labeled two breast cancer binding antibodies, anti-ErbB2 and anti-EpCAM, with infrared fluorescence dyes of different wavelengths and determined their in vivo distribution in a breast cancer xenograft model using a near-infrared (NIR) fluorescence imaging system. Our data show that these two antibodies can be readily assessed simultaneously in mouse xenograft model. This will help guide design of dosing strategies for multiple antibodies and identify potential interaction that could affect pharmacokinetics and possible side effects.
Insights
Researchers simultaneously tracked two breast cancer antibodies, anti-ErbB2 and anti-EpCAM, in mice using near-infrared imaging. This method aids in designing combination antibody therapies and understanding their interactions, pharmacokinetics, and side effects.
Area of Science:
- Oncology
- Immunology
- Biomedical Imaging
Background:
- Antibodies are crucial in cancer treatment, with combination therapies showing promise for improved outcomes.
- Targeting multiple cancer markers can enhance therapeutic efficacy.
- Understanding the in vivo behavior of multiple antibodies is essential for effective treatment design.
Purpose of the Study:
- To develop and validate a method for simultaneous in vivo assessment of two breast cancer-targeting antibodies.
- To evaluate the distribution of fluorescently labeled anti-ErbB2 and anti-EpCAM antibodies in a breast cancer xenograft model.
- To provide a foundation for optimizing combination antibody dosing and predicting pharmacokinetic interactions.
Main Methods:
- Breast cancer xenograft models were established in mice.
- Two antibodies, anti-ErbB2 and anti-EpCAM, were labeled with distinct infrared fluorescence dyes.
- Near-infrared (NIR) fluorescence imaging was employed to determine the in vivo distribution of both antibodies simultaneously.
Main Results:
- The simultaneous detection and assessment of both labeled antibodies in the mouse xenograft model were successful.
- The near-infrared fluorescence imaging system effectively visualized the distribution of anti-ErbB2 and anti-EpCAM antibodies.
- The study demonstrated the feasibility of tracking multiple antibodies concurrently in vivo.
Conclusions:
- Simultaneous in vivo imaging of multiple antibodies is achievable and valuable for preclinical cancer research.
- This approach can guide the design of combination antibody dosing strategies.
- The method facilitates the identification of potential pharmacokinetic interactions and side effects of combined antibody therapies.
